Literature DB >> 2557107

Peripheral neuropathy and mesalazine.

D K Woodward1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2557107      PMCID: PMC1838057          DOI: 10.1136/bmj.299.6709.1224-a

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  8 in total

1.  Sulfasalazine toxic reactions. Hepatitis, fever, and skin rash with hypocomplementemia and immune complexes.

Authors:  A A Mihas; D J Goldenberg; R L Slaughter
Journal:  JAMA       Date:  1978-06-16       Impact factor: 56.272

2.  Neurotoxicity associated with a reaction to sulphasalazine.

Authors:  I W Wallace
Journal:  Practitioner       Date:  1970-06

3.  Combined hepatotoxicity and neurotoxicity following sulphasalazine administration.

Authors:  M D Smith; G E Gibson; R Rowland
Journal:  Aust N Z J Med       Date:  1982-02

4.  Clinical efficacy of oral 5-aminosalicylic acid in the treatment of inflammatory bowel disease.

Authors:  U Klotz
Journal:  Am J Gastroenterol       Date:  1985-08       Impact factor: 10.864

5.  Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype.

Authors:  K M Das; M A Eastwood; J P McManus; W Sircus
Journal:  N Engl J Med       Date:  1973-09-06       Impact factor: 91.245

6.  Adverse reactions to salicylazosulfapyridine (azulfidine) in the treatment of ulcerative colitis.

Authors:  J R Collins
Journal:  South Med J       Date:  1968-04       Impact factor: 0.954

7.  Sensorimotor neuropathy with sulphasalazine.

Authors:  T R Price
Journal:  Postgrad Med J       Date:  1985-02       Impact factor: 2.401

8.  Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse.

Authors:  S A Riley; V Mani; M J Goodman; M E Herd; S Dutt; L A Turnberg
Journal:  Gut       Date:  1988-05       Impact factor: 23.059

  8 in total
  3 in total

1.  Lack of evidence for fibrosing colonopathy by 5-ASA in humans.

Authors:  M L Borum; A L Ginsberg
Journal:  Dig Dis Sci       Date:  1999-07       Impact factor: 3.199

Review 2.  Hypersensitivity to 5-ASA suppositories.

Authors:  M L Borum; A Ginsberg
Journal:  Dig Dis Sci       Date:  1997-05       Impact factor: 3.199

3.  Direct and metabolism-dependent toxicity of sulphasalazine and its principal metabolites towards human erythrocytes and leucocytes.

Authors:  M Pirmohamed; M D Coleman; F Hussain; A M Breckenridge; B K Park
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.